{"id":7833,"date":"2024-10-14T08:33:00","date_gmt":"2024-10-14T08:33:00","guid":{"rendered":"https:\/\/www.acarix.com\/acarix-secures-expansion-order-from-existing-cadscor-system-customer\/"},"modified":"2024-11-18T19:04:30","modified_gmt":"2024-11-18T19:04:30","slug":"acarix-secures-expansion-order-from-existing-cadscor-system-customer","status":"publish","type":"post","link":"https:\/\/d.ptpl.dev\/acarix\/acarix-secures-expansion-order-from-existing-cadscor-system-customer\/","title":{"rendered":"Acarix Secures Expansion Order from Existing CADScor System Customer"},"content":{"rendered":"
\n

Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, is pleased to announce that a current customer has placed an order for use of additional four CADScor Systems to extend the availability of the diagnostic tool across all their locations. This expansion underscores the customer’s continued trust in the technology as a valuable solution for early risk assessment of coronary artery disease (CAD).<\/strong><\/p>\n

“We are thrilled to see the continued market confidence in the CADScor System.” said Aamir Mahmood, CEO of Acarix. “The healthcare provider’s decision to expand the use of the CADScor System to all of their locations validates the effectiveness of our solution in identifying patients at risk for CAD, and it supports our vision to make early diagnosis more accessible. This expansion is a great example of how our technology is being integrated as a core component in advanced healthcare delivery.”<\/p>\n<\/div>\n

\n

For more information contact:<\/strong>
Jennifer Monies, phone +1 (405) 550-8144, jmonies@saxum.com<\/a><\/p>\n<\/div>\n

\n

About Acarix<\/strong><\/p>\n\n\n\n
Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n

Attachments<\/strong>
Acarix Secures Expansion Order from Existing CADScor System Customer<\/a><\/p>\n<\/div>\n